Background: We performed a retrospective investigation to assess the efficacy of chemotherapy and rituximab as front-line treatment for primary bone lymphoma (PBL). Patients and Methods: Between 1999 and 2009, 21 previously untreated patients received a diagnosis of PBL. All the patients were treated with anthracycline-containing chemotherapeutic regimens, with the addition of rituximab; 11 patients received consolidative radiation therapy after induction treatment. Results: Patients' median age was 34 years (range, 18-82 years); all presented with diffuse large B-cell lymphoma. Complete responses were seen in 95.2% of the patients treated. No relapses were observed at a median follow-up of 43.9 months. Eight-year overall survival and disease-free survival were 95.2% and 100.0%, respectively. Conclusion: These data indicate that the combined chemotherapy plus rituximab treatment may represent a suitable front-line approach in PBL, with a high rate of responses and an excellent long-term survival.
Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, Derenzini E, et al. (2011). Primary Bone Lymphoma: Evaluation odf Chemoimmunotherapy as Front-line Treatment in 21 Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 11(4), 321-325 [10.1016/j.clml.2011.03.021].
Primary Bone Lymphoma: Evaluation odf Chemoimmunotherapy as Front-line Treatment in 21 Patients
RUGGIERI, PIETRO;BROCCOLI, ALESSANDRO;Argnani L;MERCURI, MARIO;ZINZANI, PIER LUIGI
2011
Abstract
Background: We performed a retrospective investigation to assess the efficacy of chemotherapy and rituximab as front-line treatment for primary bone lymphoma (PBL). Patients and Methods: Between 1999 and 2009, 21 previously untreated patients received a diagnosis of PBL. All the patients were treated with anthracycline-containing chemotherapeutic regimens, with the addition of rituximab; 11 patients received consolidative radiation therapy after induction treatment. Results: Patients' median age was 34 years (range, 18-82 years); all presented with diffuse large B-cell lymphoma. Complete responses were seen in 95.2% of the patients treated. No relapses were observed at a median follow-up of 43.9 months. Eight-year overall survival and disease-free survival were 95.2% and 100.0%, respectively. Conclusion: These data indicate that the combined chemotherapy plus rituximab treatment may represent a suitable front-line approach in PBL, with a high rate of responses and an excellent long-term survival.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
